8-K - 22nd Century Group, Inc. (0001347858) (Filer)

10-Q - 22nd Century Group, Inc. (0001347858) (Filer)

EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

424B3 - 22nd Century Group, Inc. (0001347858) (Filer)

S-3 - 22nd Century Group, Inc. (0001347858) (Filer)

DEF 14A - 22nd Century Group, Inc. (0001347858) (Filer)

8-K - 22nd Century Group, Inc. (0001347858) (Filer)

PRE 14A - 22nd Century Group, Inc. (0001347858) (Filer)

424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

8-K - 22nd Century Group, Inc. (0001347858) (Filer)

Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple CategoriesMocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)All figures reported below reflect continuing operations, excludin

Third quarter 2023 net revenue of $17.8 millionExpanded VLN® availability to more than 4,550 stores in 19 statesProposed FDA menthol ban regulation now undergoing review at OMBGVB bulk ingredient volume of 49,000 kg shippedInitiated over $15 million in annualized operating cost reductionsReduced principal debt balances by $8.1 million in October 2023 BUFFALO, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the third quarter ended September 30, 2023, and provi

Second Quarter 2023 Net Revenues Increased 62% to $23.4 MillionLaunched VLN® Sales in California, Texas and FloridaDelivered Record GVB Ingredient Volumes as Dominant Supplier in North AmericaInitiated Operating Cost Reduction Program Targeting $15+ Million in Annualized SavingsUpdated 2023 Revenue Outlook to a Range of $80 Million to $90 Million to Reflect Revised VLN® Rollout Timelines and Transitioning GVB Ingredient Volumes Back to Internal Production BUFFALO, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco,

Immediately Accretive Addition to the Hemp/Cannabis Business with Positive EBITDA 1,276 Novel Food Applications for Cannabinoid Products to Accelerate Growth in the U.K. and EU Food and Nutraceuticals Markets BUFFALO, NY, Jan. 24, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the acquisition of privately held RX Pharmatech Ltd (RXP), a leading United Kingdom distributor of cannabinoids with 1,276 novel food applications with the U.K. Food Standards Agency (FSA). Terms of the agreement include an up-front paymen

BUFFALO, N.Y., Oct. 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, will release third quarter 2022 financial results on Tuesday, November 8, 2022, at 6:00 a.m. ET. In conjunction with the news release, 22nd Century Group will host a conference call at 10:00 a.m. ET on the same day. During the webcast, James A. Mish, chief executive officer, John Miller, president of 22nd Century's tobacco business, and Hugh Kinsman, chief financial officer, will provide an update on the Company and review third quarter 2022 res

Provides Transformational Platform to Rapidly Grow Hemp/Cannabis FranchiseTransaction Immediately Accretive and Will Double Company's Total RevenueAdds Significant Commercial Scale to Existing Hemp/Cannabis FranchiseGVB Biopharma has Achieved Strong Growth and Leading Market Share in Hemp-Derived Active Ingredients BUFFALO, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CD

BUFFALO, N.Y., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced entry into the global specialty hops market, its third and newest plant franchise. The Company released an update letter to shareholders from CEO James A. Mish describing its opportunities and plans in this market. The Company also posted an overview deck describing its entry into the hops market in the Investor Relations section of the corporate website at www.xxiicentury.com/investors. Dear Fellow Shareholders, Following the exciting progress in our tobacco

Initiated International Launch Process For VLN®, First Sales Planned by First Quarter 2022First Revenue From Hemp/Cannabis Franchise to Commence in Second Half of 2021Third Plant-Based Franchise to be Introduced on August 30, 2021Uplisting common shares to the Nasdaq Capital Market ("Nasdaq") and will continue to trade under current symbol, "XXII"Record Second Quarter Net Sales of $8.4 Million, Up Greater Than 30% From the Second Quarter of 2020Executing From a Strong Financial Position with Cash and Cash Equivalents of $62.3 Million as of June 30, 2021. BUFFALO, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a leading plant-based biotechnology com

GAINERS: Global Hemp Group (OTC:GBHPF) shares closed up 117.39% at $0.04 CordovaCann (OTC:LVRLF) shares closed up 19.90% at $0.06 SOL Glb Inv (OTC:SOLCF) shares closed up 19.40% at $0.06 1933 Industries (OTC:TGIFF) shares closed up 11.81% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.37% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 6.01% at $0.04 22nd Century Group (NASDAQ:XXII) shares closed up 4.77% at $0.72 EnWave (OTC:NWVCF) shares closed up 4.53% at $0.17 Psychemedics (NASDAQ:PMD) shares closed up 3.52% at $2.24 cbdMD (AMEX:YCBD) shares closed up 3.11% at $0.63 LOSERS: Green Growth Brands (OTC:GGBXF) shares closed down 99.00% at $1e-06 Leafbuyer Techs (OTC:LBUY)

GAINERS: Leafbuyer Techs (OTC:LBUY) shares closed up 3900.00% at $0.02 Heritage Cannabis Holding (OTC:HERTF) shares closed up 125.00% at $0.00 AusCann Group Holdings (OTC:ACNNF) shares closed up 50.00% at $0.01 Cann Gr (OTC:CNGGF) shares closed up 37.50% at $0.02 Target Group (OTC:CBDY) shares closed up 30.59% at $0.00 Canopy Gwth (NASDAQ:CGC) shares closed up 17.25% at $8.35 RIV Capital (OTC:CNPOF) shares closed up 13.33% at $0.10 GrowGeneration (NASDAQ:GRWG) shares closed up 13.03% at $2.66 Auxly Cannabis Group (OTC:CBWTF) shares closed up 12.60% at $0.03 SNDL (NASDAQ:SNDL) shares closed up 9.66% at $2.27 Aurora Cannabis (NASDAQ:ACB) shares closed up 8.87% at $6.25 Village Farms Intl (NAS

GAINERS: Pharmadrug (OTC:LMLLF) shares closed up 85.78% at $0.01 Heritage Cannabis Holding (OTC:HERTF) shares closed up 66.67% at $0.001 Cann Gr (OTC:CNGGF) shares closed up 37.93% at $0.02 4Front Ventures (OTC:FFNTF) shares closed up 27.16% at $0.10 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Kaya Holdings (OTC:KAYS) shares closed up 22.97% at $0.04 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 17.19% at $0.01 Body and Mind (OTC:BMMJ) shares closed up 12.02% at $0.03 Cansortium (OTC:CNTMF) shares closed up 10.62% at $0.12 Cara Therapeutics (NASDAQ:CARA) shares closed up 10.45% at $0.37 Auxly Cannabis Group (OTC:CBWTF) shares closed up 8.56% at $0.03 Scotts Miracle Gro

GAINERS: Zelira Therapeutics (OTC:ZLDAF) shares closed up 69.95% at $0.48 Global Hemp Group (OTC:GBHPF) shares closed up 40.00% at $0.03 CordovaCann (OTC:LVRLF) shares closed up 29.03% at $0.04 Elixinol Wellness (OTC:ELLXF) shares closed up 25.00% at $0.00 Eastside Distilling (NASDAQ:EAST) shares closed up 23.57% at $1.20 Body and Mind (OTC:BMMJ) shares closed up 15.70% at $0.04 Pharmadrug (OTC:LMLLF) shares closed up 15.25% at $0.01 1933 Industries (OTC:TGIFF) shares closed up 14.86% at $0.01 Maple Leaf Green World (OTC:MGWFF) shares closed up 10.69% at $0.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 10.42% at $58.92 Rocky Mountain High (OTC:RMHB) shares closed up 8.33% at $0.0

GAINERS: Australis Capital (OTC:AUSAF) shares closed up 9900.00% at $0.0001 Cara Therapeutics (NASDAQ:CARA) shares closed up 25.84% at $0.37 4Front Ventures (OTC:FFNTF) shares closed up 23.42% at $0.10 Cannabix Technologies (OTC:BLOZF) shares closed up 15.92% at $0.43 Global Compliance (OTC:FUAPF) shares closed up 12.75% at $0.01 22nd Century Group (NASDAQ:XXII) shares closed up 11.92% at $0.79 Curaleaf Holdings (OTC:CURLF) shares closed up 9.71% at $4.18 SOL Glb Inv (OTC:SOLCF) shares closed up 9.05% at $0.04 OrganiGram Holdings (NASDAQ:OGI) shares closed up 7.59% at $1.70 RIV Capital (OTC:CNPOF) shares closed up 7.14% at $0.10 GrowGeneration (NASDAQ:GRWG) shares closed up 6.82% at $2.35 A

GAINERS: MJ Holdings (OTC:MJNE) shares closed up 44.44% at $0.00 CLS Holdings USA (OTC:CLSH) shares closed up 15.83% at $0.05 Maple Leaf Green World (OTC:MGWFF) shares closed up 11.28% at $0.03 Rocky Mountain High (OTC:RMHB) shares closed up 8.27% at $0.01 Charlottes Web Holdings (OTC:CWBHF) shares closed up 5.92% at $0.17 Greenlane Hldgs (NASDAQ:GNLN) shares closed up 5.88% at $0.26 Zoned Props (OTC:ZDPY) shares closed up 5.28% at $0.66 22nd Century Group (NASDAQ:XXII) shares closed up 4.09% at $0.71 Aurora Cannabis (NASDAQ:ACB) shares closed up 3.74% at $5.69 EnWave (OTC:NWVCF) shares closed up 3.57% at $0.17 Tilray Brands (NASDAQ:TLRY) shares closed up 3.41% at $1.83 Cara Therapeutics (N

GAINERS: AusCann Group Holdings (OTC:ACNNF) shares closed up 50.00% at $0.01 Rocky Mountain High (OTC:RMHB) shares closed up 26.98% at $0.02 Zelira Therapeutics (OTC:ZLDAF) shares closed up 21.10% at $0.28 4Front Ventures (OTC:FFNTF) shares closed up 15.38% at $0.09 Blueberries Medical (OTC:BBRRF) shares closed up 14.35% at $0.01 Global Compliance (OTC:FUAPF) shares closed up 10.00% at $0.01 Greenlane Hldgs (NASDAQ:GNLN) shares closed up 8.63% at $0.29 SOL Glb Inv (OTC:SOLCF) shares closed up 6.32% at $0.04 Belgravia Hartford Cap (OTC:BLGVF) shares closed up 6.30% at $0.02 CLS Holdings USA (OTC:CLSH) shares closed up 6.27% at $0.05 Eastside Distilling (NASDAQ:EAST) shares closed up 6.00% at

- Bloomberg

GAINERS: Affinor Growers (OTC:RSSFF) shares closed up 76.74% at $0.17 Global Compliance (OTC:FUAPF) shares closed up 39.00% at $0.01 CNBX Pharmaceuticals (OTC:CNBX) shares closed up 33.33% at $0.01 Elixinol Wellness (OTC:ELLXF) shares closed up 32.50% at $0.00 SOL Glb Inv (OTC:SOLCF) shares closed up 18.50% at $0.05 Target Group (OTC:CBDY) shares closed up 10.90% at $0.00 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 9.17% at $49.40 Auxly Cannabis Group (OTC:CBWTF) shares closed up 7.14% at $0.02 Cara Therapeutics (NASDAQ:CARA) shares closed up 7.02% at $0.26 Cannabix Technologies (OTC:BLOZF) shares closed up 4.24% at $0.35 Cansortium (OTC:CNTMF) shares closed up 3.85% at $0.14 CLS

GAINERS: 1933 Industries (OTC:TGIFF) shares closed up 25.00% at $0.01 Target Group (OTC:CBDY) shares closed up 24.80% at $0.00 4Front Ventures (OTC:FFNTF) shares closed up 14.67% at $0.09 SOL Glb Inv (OTC:SOLCF) shares closed up 11.42% at $0.04 Auxly Cannabis Group (OTC:CBWTF) shares closed up 11.41% at $0.02 Pharmadrug (OTC:LMLLF) shares closed up 8.42% at $0.02 iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 7.76% at $0.02 RIV Capital (OTC:CNPOF) shares closed up 6.73% at $0.11 C21 Investments (OTC:CXXIF) shares closed up 5.00% at $0.27 CV Sciences (OTC:CVSI) shares closed up 4.09% at $0.06 EnWave (OTC:NWVCF) shares closed up 3.70% at $0.17 Corbus Pharmaceuticals (NASDAQ:CRBP) shares c

Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea

Further Enhances 22nd Century Group's Deep Expertise in Plant-Based Biotechnology BUFFALO, N.Y., April 11, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced the appointment of Dr. Calvin Treat as Chief Scientific Officer, effective May 23, 2022. In this new role, Dr. Treat will lead the expanding scientific, research and technological operations of the company, leveraging its expertise, IP, and partnerships across all three of its alkaloid plant franchises toward becoming a global leader in specia

Carmines has submitted hundreds of PMTAs to the FDA and spearheaded the successful MRTPA submitted by 22nd Century Group (NASDAQ:XXII) that won an FDA marketing order in December 2021.COSTA MESA, CA / ACCESSWIRE / March 2, 2022 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium, nicotine-based, e-cigarette space, today announced the appointment of Edward Carmines, Ph.D., to its Board of Directors. Dr. Carmines is an accomplished scientist and regulatory affairs expert with extensive experience working with the Center for Tobacco Products at the U.S. Food and Drug Administration ("FDA"). In addition to an extraordinary record of success w

FDA's Rulemaking Process Could Make VLN® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market Opportunity to Accelerate FDA's Plan to Cap Nicotine in Cigarettes at Levels Already Achieved in 22nd Century's VLN® Products BUFFALO, N.Y., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, congratulates Dr. Robert Califf on his confirmation as FDA Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is known to be a longtime proponent of innovative tobacco

BUFFALO, N.Y, Jan. 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced the appointment of James A. Mish to its Board of Directors (Board). The addition of Mr. Mish, who currently serves as Chief Executive Officer at 22nd Century, significantly enhances the Board's depth of experience in the commercialization of science-driven consumer products as the Company prepares to launch its first reduced nicotine content tobacco products and commercially modified hemp/cannabis plant lines. "Th

Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company's Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced the appointment of Anthony Johnson to its Board of Directors. Mr. Johnson is an accomplished life sciences and biotechnology executive leader with broad expertise in corporate strategy, technology development, marketing, and business development. Mr. Johnson will serve as a member of

To Date, 22nd Century Has Provided More Than 31 Million Variable Nicotine Content Research Cigarettes for Numerous Independent Scientific Studies Research on Nicotine Content Reduction in Cigarettes Underpins the FDA's Proposed Mandate to Reduce Nicotine Levels in All Cigarettes Sold in the U.S. to "Minimally or Non-Addictive" Levels, a Feat Already Achieved by VLN® Delivery of Research Cigarettes is to Support Nicotine Cap Mandate and is Unrelated to 22nd Century's Modified Risk Tobacco Product (MRTP) Application for VLN® Cigarettes BUFFALO, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on to

22nd Century’s Proprietary VLN® King and VLN® Menthol King Poised to Play a Central Role in Making FDA’s Reduced Nicotine Mandate FeasibleMRTP Authorization of VLN® King and VLN® Menthol King Will Serve as a Major Catalyst for the FDA to Accelerate RuleContaining 95% Less Nicotine than Traditional Cigarettes, VLN® is the Only Combustible Tobacco Product that Complies with the FDA’s Proposed Nicotine Cap WILLIAMSVILLE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it continues

Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

Cowen initiated coverage of 22nd Century Group with a rating of Outperform and set a new price target of $5.00

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

4 - 22nd Century Group, Inc. (0001347858) (Issuer)

4 - 22nd Century Group, Inc. (0001347858) (Issuer)

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

4 - 22nd Century Group, Inc. (0001347858) (Issuer)

4 - 22nd Century Group, Inc. (0001347858) (Issuer)

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

3 - 22nd Century Group, Inc. (0001347858) (Issuer)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)